PARLIAMENTARY DEBATE
Medicine Supply Chain: Community Pharmacies - 17 June 2025 (Commons/Commons Chamber)

Increasing the resilience of the UK medical supply chain is a key priority. I regularly meet the team to routinely take action to mitigate supply issues, including requesting additional stock, identifying alternative global sources and issuing management advice. Although the Department has no plans to conduct a specific review, we constantly work to identify and take forward further actions to reduce the impact of medicine shortages, including targeted winter monitoring.

Having worked in community pharmacies for nearly 20 years, I have witnessed at first hand the pain that medicine shortages can cause North Somerset patients and their loved ones. Will the Minister meet me, along with my hon. Friend the Member for Exeter (Steve Race) and other members of the all-party parliamentary group on pharmacy, to discuss the outcome of our inquiry into these shortages?

I congratulate my hon. Friend and constituency neighbour on his dedicated career in community pharmacy, and thank him for the expertise that he brings to the work of the all-party parliamentary group to help Members understand the impact of this issue on patients and pharmacies. I am planning to hold a parliamentary event on the subject in the autumn, and I am keen to work with the APPG to make it a success for all Members.

The long-term viability of pharmacies and, indeed, the whole NHS was under threat from the right hon. Gentleman and his party, but thanks to this Government, it is being made fit for the future. This is a serious issue for all our constituents, and we want to make the system work better. The right hon. Gentleman will see from the 10-year plan that we will make the NHS fit for his constituents, mine and those of every other Member.

I call the Liberal Democrat spokesperson.

Across the country, community pharmacies struggle not only with supply chain problems but with dispensing some of the critical medicines for our constituents at a loss. I was concerned to read that higher prices for United States pharmaceuticals are on the table for the next stage of trade negotiations with Donald Trump, because an additional £1.5 billion would cost both the NHS and our community pharmacies dear. What steps is the Department taking to ensure that the NHS, and the vital medicine supply on which we rely, will not be used as a bargaining chip in a trade deal with a highly unreliable US President?

The hon. Lady has asked an important question about the pharmaceutical industry, which is key to the country’s growth mission and to supporting all our constituents and the entire country. As we know, my right hon. Friend the Prime Minister is currently attending the G7 summit. We have good relationships with America, and the Department is working closely across Government to ensure that the same stability of supply remains for our constituents.